Atossa Genetics Inc. (NASDAQ:ATOS) – Investment analysts at Zacks Investment Research boosted their FY2017 earnings per share estimates for shares of Atossa Genetics in a note issued to investors on Tuesday. Zacks Investment Research analyst G. Zeng now forecasts that the company will earn ($0.84) per share for the year, up from their previous forecast of ($1.64). Zacks Investment Research also issued estimates for Atossa Genetics’ Q4 2017 earnings at ($0.07) EPS, FY2018 earnings at ($0.30) EPS, FY2019 earnings at ($0.31) EPS and FY2020 earnings at ($0.21) EPS.

ILLEGAL ACTIVITY NOTICE: “Analysts Offer Predictions for Atossa Genetics Inc.’s FY2017 Earnings (ATOS)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at

Shares of Atossa Genetics (NASDAQ ATOS) opened at $0.33 on Friday. Atossa Genetics has a 52 week low of $0.31 and a 52 week high of $2.60.

A hedge fund recently bought a new stake in Atossa Genetics stock. Sabby Management LLC bought a new stake in shares of Atossa Genetics Inc. (NASDAQ:ATOS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 291,046 shares of the company’s stock, valued at approximately $150,000. Sabby Management LLC owned 2.49% of Atossa Genetics as of its most recent SEC filing. Institutional investors own 8.13% of the company’s stock.

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Receive News & Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.